Needle-Free semaglutide patch enters first human safety trial

NCT ID NCT07539415

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a microneedle patch called DWRX5003 that delivers semaglutide, a drug used for obesity and type 2 diabetes. The study involves 72 healthy adults to check safety and how well the drug enters the body compared to standard injections. It is not yet testing in people with the conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Semaglutide (in a microneedle patch)

What this could lead to

If successful, this could lead to a needle-free way to deliver semaglutide for weight management and diabetes control.

What could go wrong

This is a very early Phase 1 safety study in healthy volunteers, not patients. The patch may not deliver the drug effectively or could cause skin reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seoul National University Hospital

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••